Abstract:Objective:To investigate the clinical characteristics, biological functions and molecular mechanism of polo-like Kinase 4 (Plk4) in gliomas.Methods:We studied the transcriptome data of glioma samples and clinical data of glioma patients in the Cancer Genome Atlas (TCGA) database (689 cases) and the Chinese Glioma Genome Atlas (CGGA) database (693 cases), and transcriptome data of normal brain tissue specimens in the GTEx database (255 cases) were also included. The differences in the expression of Plk4 in glioma specimens and normal brain tissues and glioma specimens of different pathological grades were compared. Log-rank test was used to compare the differences in overall survival between patients with low Plk4 expression and high expression groups. We took human astrocytes, U87, LN229, U251 and A172 cell lines for related research. Small interfering RNA (siRNA) transfection method was used to knock down the expression of Plk4 in U87 and LN229 cells. Real-time fluorescent quantitative polymerase chain reaction was used to detect the expression of Plk4 mRNA. Western blotting was used to detect the expression of Plk4 protein. EdU experiment and Transwell experiment were used to observe the effect of Plk4 on the proliferation, migration and invasion of glioma cells. Twenty 4-week-old female BALB/c-nu nude mice were taken, and U87 cells were injected into the abdomen of mice to prepare glioma xenogeneic tumor-bearing models. The differences in tumor volume and weight were analyzed between the Plk4 knockdown treatment group (intratumor injection of siRNA-Plk4) and the control group (injection of non-sequence Plk4) after 21 d (7 times) of treatment. We took U87 cells with knocked down Plk4, and used proteomics and phosphorylation analysis to explore the molecular mechanism of Plk4's biological function in gliomas.Results:Compared with astrocytes, the expression level of PLk4 mRNA in U87, LN229, U251 and A172 glioma cells was higher. TCGA combined with GTEx database data analysis showed that the expression level of Plk4 mRNA in low-grade glioma and glioblastoma specimens was higher than that in normal brain tissue. Analysis of the samples in the CGGA database showed that the expression level of Plk4 mRNA increased with the increase of the WHO pathological grade. In both databases, the overall survival of patients with high expression of Plk4 was shorter than that of patients with low expression of Plk4. The EdU experiment showed that the EdU positive rate of U87 and LN229 cells that knocked down Plk4 expression was lower than that of nonsense sequence cells. Transwell experiments showed that U87 and LN 229 cells that knocked down Plk4 expression had lower number of gel penetration than nonsense sequence cells. In vivo results showed that the growth rate of subcutaneous tumor in nude mice with Plk4 knockdown was significantly reduced. The differences in the above data were statistically significant (all P<0.01 or 0.05). In proteomics analysis, a total of 428 differentially expressed proteins were identified. In the phosphorylation analysis, a total of 1 180 differentially expressed phosphorylated peptides were identified, corresponding to 728 phosphorylated proteins. Correlation analysis of the results of proteomics and phosphorylation revealed that there were 2 197 proteins associated with proteomics and phosphorylation, of which 66 were only changed at the protein level, only 590 changed at the phosphorylation level, and 25 changed at both protein and phosphorylation levels. The GO function annotation and KEGG pathway enrichment analysis of 590 proteins with only changes at phosphorylation level found that the functions of 590 proteins were mainly protein binding and cadherin binding, etc. The main enrichment pathways were neurotrophic protein signaling pathway and long-term enhancement, etc. Conclusions:Plk4 is highly expressed in brain gliomas, which may be related to the prognosis of patients. Its mechanism may be related to the promotion of the proliferation, migration and invasion of glioma cells through signal pathways such as neurotrophic signaling pathway. Plk4 may be a molecular marker for the diagnosis and prognosis of glioma and a potential target for drug therapy.

Knocking down of Polo-like kinase 2 inhibits cell proliferation and induced cell apoptosis in human glioma cells

Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma

Silencing of polo-like kinase 2 increases cell proliferation and decreases apoptosis in SGC-7901 gastric cancer cells.

PLK1 Inhibition Promotes Apoptosis and DNA Damage in Glioma Stem Cells by Regulating the Nuclear Translocation of YBX1

Knockdown of Akt2 Expression by Rna Interference Inhibits Proliferation, Enhances Apoptosis, and Increases Chemosensitivity to the Anticancer Drug Vm-26 in U87 Glioma Cells

Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer.

Knockdown of PKCε Expression Inhibits Growth, Induces Apoptosis and Decreases Invasiveness of Human Glioma Cells Partially Through Stat3

The Balance of Polo-like Kinase 1 in Tumorigenesis

Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling

AKT2-knockdown Suppressed Viability with Enhanced Apoptosis, and Attenuated Chemoresistance to Temozolomide of Human Glioblastoma Cells in Vitro and in Vivo.

P11.52 Reduced Expression of Proteolipid Protein 2 Increases ER-stress-induced Apoptosis and Autophagy in Glioblastoma

Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer.

Knockdown of Angiopoietin-Like Protein 2 Inhibits Proliferation and Invasion in Glioma Cells Via Suppressing the ERK/MAPK Signaling Pathway.

PLK1 Expression in Gliomas and Its Correlation to Tumor Proliferative Activity and Prognosis

Depletion of CLK2 Sensitizes Glioma Stem-Like Cells to PI3K/mTOR and FGFR Inhibitors.

Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme

Inhibitory Effect of Polo-like Kinase 1 Depletion on Mitosis and Apoptosis of Gastric Cancer Cells

Study on the function and molecular mechanism of Plk4 in gliomas

Polo‑like Kinase4 Promotes Tumorigenesis and Induces Resistance to Radiotherapy in Glioblastoma

Reduced Expression of Proteolipid Protein 2 Increases ER Stress‐induced Apoptosis and Autophagy in Glioblastoma

PLK4 Initiates Crosstalk Between Cell Cycle, Cell Proliferation and Macrophages Infiltration in Gliomas